Trade VBI Vaccines Inc. - VBIV CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023374% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001151% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 0.52 |
| Open | 0.52 |
| 1-Year Change | -60% |
| Day's Range | 0.52 - 0.53 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jul 29, 2024 | 0.53 | 0.00 | 0.00% | 0.53 | 0.53 | 0.52 |
| Jul 26, 2024 | 0.52 | 0.01 | 1.96% | 0.51 | 0.53 | 0.50 |
| Jul 25, 2024 | 0.52 | 0.01 | 1.96% | 0.51 | 0.52 | 0.48 |
| Jul 24, 2024 | 0.53 | -0.03 | -5.36% | 0.56 | 0.56 | 0.51 |
| Jul 23, 2024 | 0.56 | -0.01 | -1.75% | 0.57 | 0.58 | 0.54 |
| Jul 22, 2024 | 0.59 | 0.03 | 5.36% | 0.56 | 0.61 | 0.55 |
| Jul 19, 2024 | 0.57 | -0.07 | -10.94% | 0.64 | 0.65 | 0.57 |
| Jul 18, 2024 | 0.63 | -0.07 | -10.00% | 0.70 | 0.72 | 0.59 |
| Jul 17, 2024 | 0.70 | -0.02 | -2.78% | 0.72 | 0.72 | 0.69 |
| Jul 16, 2024 | 0.70 | -0.04 | -5.41% | 0.74 | 0.75 | 0.70 |
| Jul 15, 2024 | 0.73 | -0.03 | -3.95% | 0.76 | 0.76 | 0.73 |
| Jul 12, 2024 | 0.76 | 0.02 | 2.70% | 0.74 | 0.77 | 0.72 |
| Jul 11, 2024 | 0.74 | 0.01 | 1.37% | 0.73 | 0.75 | 0.70 |
| Jul 10, 2024 | 0.73 | 0.01 | 1.39% | 0.72 | 0.73 | 0.70 |
| Jul 9, 2024 | 0.72 | -0.01 | -1.37% | 0.73 | 0.73 | 0.70 |
| Jul 8, 2024 | 0.72 | 0.00 | 0.00% | 0.72 | 0.74 | 0.72 |
| Jul 5, 2024 | 0.70 | -0.01 | -1.41% | 0.71 | 0.71 | 0.68 |
| Jul 3, 2024 | 0.70 | -0.02 | -2.78% | 0.72 | 0.75 | 0.69 |
| Jul 2, 2024 | 0.69 | 0.04 | 6.15% | 0.65 | 0.75 | 0.65 |
| Jul 1, 2024 | 0.66 | 0.02 | 3.13% | 0.64 | 0.67 | 0.64 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
VBI Vaccines Inc. Company profile
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company''s enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901. In addition, it engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. The company primarily serves physicians and pharmacists through direct sales. It has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. The company also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. VBI Vaccines Inc. has collaboration with Coalition For Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.| Industry: | Biotechnology & Medical Research (NEC) |
160 Second Street
Cambridge
CAMBRIDGE
MASSACHUSETTS 02142
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com